Factors influencing elimination and distribution of fleroxacin: Metaanalysis of individual data from 10 pharmacokinetic studies

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 3, 1996, Pages 575-580

  Reigner, B G ^a   Welker, H A ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; FLEROXACIN;

ADULT; AGE; AGED; ARTICLE; BODY SURFACE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; FEMALE; GENDER; HUMAN; HUMAN EXPERIMENT; MALE; META ANALYSIS; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; VOLUNTEER;

EID: 0030044180     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.3.575     Document Type: Article

References (36)

1. Association of British Pharmaceutical Industry. 1988. Guidelines on good clinical research practice Association of British Pharmaceutical Industry, London.
2. Heal, S., and L. Sheiner. 1980. The NONMEM system. Am. Stat. 34:118-119.
3. Boeckmann, A., L. B. Sheiner, and S. L. Beal. 1991. NONMEM users' guide, part V. Introductory guide, p. 23 and 123. NONMEM Project Group, University of California at San Francisco, San Francisco.
4. Cakmakci, M., L. Gossweiler, J. Schilling, R. Schlumpf, and S. Geroulanos. 1992 Penetration of fleroxacin into human lung, muscle, and fat tissue. Drugs Expt. Clin. Res. 28:299-302.
5. Cockcroft, D. W., and M. H. Gault. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41
6. De Lepeleire, I., A. Van Hecken, R. Verbesselt, T. B. Tjandra-Maga, and P. J. De Schepper. 1988. Comparative oral pharmacokinetics of fleroxacin and pefloxacin. J. Antimicrob. Chemother. 22:197-202
7. Dell, D., C. Partos, and R. Portmann. 1988. The determination of a new trifluorinated quinolone, fleroxacin, its N-demethyl, and N-oxide metabolites in plasma and urine by high performance liquid chromatography with fluorescence detection. J. Liquid Chromatogr. 11:1299-1312.
8. Dubois, D., and E. F. Dubois. 1916. A formula to estimate the approximate surface area if height and weight be known. Arch. Intern. Med. 17:863.
9. Gibaldi, M., and D. Perrier. 1982. Pharmacokinetics Marcel Dekker, Inc., New York
10. Hallynck, T. H., J. A. Thomis, R. Daneels, and L. Dehli. 1981. Should clearance be normalized to body surface or to lean body mass? Br. J Clin. Pharmacol. 11:523-526.
11. Heizmann, P., D. Dell, H. Eggers, and R. Gora. 1990. Determination of the new fluoroquinolone fleroxacin and its N-demethyl and N-oxide metabolites in plasma and urine by high-performance liquid chromatography with fluorescence detection. J Chromatography. 527:91-101.
12. James, W. P. T. 1976. Research on obesity Her Majesty's Stationery Office, London.
13. Kneer, J. 1990 Summary of analytical data for clinical studies with fleroxacin (Ro 23-6240) Research report B-156'683. Data on file. F. Iloffmann-La Roche Ltd., Basel.
14. Manek, N., J. M. Andrews, and R. Wise. 1986 In vitro activity of Ro 23-6240. a new difluorinated quinolone derivative, compared with that of other antimicrobial agents. Antimicrob. Agents Chemother 30:330-332.
15. Nakashima, M., M. Kanamaru, T. Uematsu, A. Takiguchi, A. Mizuno, T. Itaya, F. Kawahara, T. Ooie, S. Saito. H. Uchida, and K. Masuzawa. 1988. Clinical pharmacokinetics and tolerance of fleroxacin in healthy male volunteers. J. Antimicrob Chemother 22(Suppl. D): 133-144.
16. Novak, L. P. 1972. Aging, total body potassium, fat-free mass and cell mass in males and females between ages 18 and 85 years. J. Gerontol. 27:438-443.
17. Paganoni, R., C. H. Herzog, A. Braunsteiner, and P. Hohl. 1988. Fleroxacin: in-vitro activity worldwide against 20.807 clinical isolates and comparison to ciprofloxacin and norfloxacin. J. Antimicrob. Chemother 22(Suppl D):3-17.
18. Peck, C. C., and J. H. Rodman. 1986. Applied pharmacokinetics. principles of therapeutic drug monitoring, 2nd ed., p. 64-67 Applied Therapeutics, Spokanc, Wash.
19. Portmann, R., and E. Weidekamm. 1992 Penetration of fleroxacin into human and animal tissues. Chemotherapy (Basel) 38:145-149.
20. Schrenzel, J., F. Cerrutti, M. Herrmann, T. Leemann, E. Weidekamm, R. Portmann. B. Hirschel, and D. P. Lew. 1994. Single dose pharmacokinetics of oral fleroxacin in bacteremic patients. Antimicrob. Agents Chemother. 38: 1219-1224
21. Sheiner, L. B. 1986. Analysis of pharmacokinetic data using parametric models. III. Hypothesis tests and confidence intervals. J. Pharmacokinet. Biopharm. 14:539-555.
22. Sheiner, L. B., B. Rosenberg, and V. V. Marathe. 1977. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet. Biopharm. 5:445-479.
23. Singlas, E., A. Leroy, E. Sultan, M. Godin, B. Moulin, A. M. Taburet, M. Dhib, and J. P. Fillastre. 1990. Disposition of fleroxacin, a new trifluoro-quinolone, and its metabolites. Pharmacokinetics in renal failure and influence of haemodialysis. Clin. Pharmacokinet. 19:67-79.
24. Snedecor, G. W., and W. G. Cochran. 1980. Statistical methods, 7th ed., p. 360-361. Iowa State University Press, Ames.
25. Soons, P. A., C. Grib, D. D. Breimer, and W. Kirch. 1992. Effects of acute febrile infectious diseases on the oral pharmacokinetics and effects of nitrendipine enantiomers and of bisoprolol Clin Pharmacokinet 23:238-248.
26. Sörgel, F., R. Metz. K. Naber, R. Seelmann, and P. Muth. 1988. Pharmacokinetics and body fluid penetration of fleroxacin in healthy volunteers J. Antimicrob. Chemother. 22(Suppl. D):155-167.
27. Sörgel, F., R. Seelmann, K. Naber, R. Metz, and P. Muth. 1988. Metabolism of fleroxacin in man. J. Antimicrob. Chemother. 22(Suppl. D):169-178.
28. Steimer, J. L. 1992 Population models and methods, with emphasis on pharmacokinetics. In M Rowland and L. Aarons (ed.), New strategies in drug development and clinical evaluation: the population approach. Commission of the European Committees, Brussels.
29. Steimer, J. L., A. Mallet, J.-L. Golmard, and J.-F. Boisvieux. 1984. Alternative approaches to estimation of population pharmacokinetic parameters comparison with the nonlinear mixed-effect model. Drug Metab. Rev. 15: 265-292.
30. Taburet, A. M., A. Devillers, P. Thomare, J.-P. Fillastre, P. Veyssier, and E. Singlas. 1990. Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in elderly patients. Clin. Pharmacokinet. 19: 80-88.
31. Weldekamm, E., R. Portmann, C. Partos, and D. Dell. 1988. Single and multiple dose pharmacokinetics of fleroxacin. J. Antimicrob. Chemother 22(Suppl. D):145-154.
32. Weidekamm, E., R. Portmann, K. Suter, C. Partos, D. Dell, and P. W. Lücker. 1987 Single- and multiple dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans. Antimicrob. Agents Chemother. 31: 1909-1914.
33. Wiltshire, H. R., H. Pearson, A. M. Betty, S. R. Harris, C. H. Muirhead, A. G. James, and J. P. Court. 1989. Metabolism of fleroxacin. Rev Infect. Dis, 11(Suppl. 5):S1130-S1131.
34. Wise, R., D. Honeyborne, J. M. Andrews, and J. P. Ashby. 1988. The penetration of fleroxacin into bronchial mucosa. J. Antimicrob. Chemother 22: 203-206.
35. Wise, R., B. Kirkpatrick, J. Ashby, and D. J. Griggs. 1987 Pharmacokinetics and tissue penetration of Ro 23-6240, a new trifluoroquinolone. Antimicrob. Agents Chemother. 31:161-163
36. Zar, H. Z. 1984. Biostatistical analysis. 2nd ed., p. 343-347. Prentice-Hall. Inc., Englewood Cliffs, N J.